Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInventory AverageInvested CapitalMarket Capitalization

RedHill Biopharma (RDHL) Gross Margin: 2013-2023

Historic Gross Margin for RedHill Biopharma (RDHL) over the last 5 years, with Jun 2023 value amounting to 55.12%.

  • RedHill Biopharma's Gross Margin rose 415.00% to 55.12% in Q2 2023 from the same period last year, while for Jun 2023 it was 42.74%, marking a year-over-year increase of 111.00%. This contributed to the annual value of 60.31% for FY2024, which is 1328.00% up from last year.
  • RedHill Biopharma's Gross Margin amounted to 55.12% in Q2 2023, which was down 0.16% from 55.21% recorded in Q1 2023.
  • In the past 5 years, RedHill Biopharma's Gross Margin ranged from a high of 75.99% in Q1 2019 and a low of -62.41% during Q1 2020.
  • Moreover, its 3-year median value for Gross Margin was 50.86% (2021), whereas its average is 46.29%.
  • As far as peak fluctuations go, RedHill Biopharma's Gross Margin crashed by 13,840bps in 2020, and later soared by 11,257bps in 2021.
  • Over the past 5 years, RedHill Biopharma's Gross Margin (Quarterly) stood at 50.44% in 2019, then crashed by 2,524bps to 25.20% in 2020, then slumped by 1,280bps to 12.40% in 2021, then spiked by 2,042bps to 32.82% in 2022, then surged by 415bps to 55.12% in 2023.
  • Its Gross Margin was 55.12% in Q2 2023, compared to 55.21% in Q1 2023 and 32.82% in Q4 2022.